We are live on ! Find out more
NFGH

Nan Fung Group Holdings Portfolio holdings

AUM $121M
1-Year Est. Return 56.89%
This Fund
S&P 500
This Quarter Est. Return
+3.58%
1 Year Est. Return
+56.89%
3 Year Est. Return
+244.35%
5 Year Est. Return
+210.19%
10 Year Est. Return
–
AUM
$145M
AUM Growth
-$11.5M
Cap. Flow
-$8.89M
Cap. Flow %
-6.13%
Top 10 Hldgs %
82.11%
Holding
47
New
8
Increased
4
Reduced
4
Closed
5

Top Buys

Rank Stock Value
1
MRUS
Merus
MRUS
+$1.65M
2
JBIO
Jade Biosciences
JBIO
+$1.05M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$836K
4
REPL icon
Replimune Group
REPL
+$709K
5
TVTX icon
Travere Therapeutics
TVTX
+$543K

Top Sells

Rank Stock Value
1
HRMY icon
Harmony Biosciences
HRMY
+$7.82M
2
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$3.42M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$1.85M
4
TRDA icon
Entrada Therapeutics
TRDA
+$1.19M
5
TSVT
2seventy bio
TSVT
+$586K

Sector Composition

Rank Sector Weight
1 Healthcare 99.77%
2 Technology 0.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TVTX icon
26
Travere Therapeutics
TVTX
$5.78B
$538K 0.37%
+25,606
New +$543K
KALV
27
DELISTED
KalVista Pharmaceuticals
KALV
$532K 0.37%
78,720
– –
ASND icon
28
Ascendis Pharma A/S
ASND
$16.8B
$509K 0.35%
4,168
– –
BMEA icon
29
Biomea Fusion
BMEA
$91.3M
$506K 0.35%
+60,000
New +$512K
ACAD icon
30
Acadia Pharmaceuticals
ACAD
$5.03B
$477K 0.33%
29,984
– –
ALXO icon
31
ALX Oncology
ALXO
$290M
$473K 0.33%
41,950
– –
AFMD
32
DELISTED
Affimed
AFMD
$462K 0.32%
37,247
+29,130
+359% +$511K
ARGX icon
33
argenx
ARGX
$54.1B
$421K 0.29%
1,110
– –
MDGL icon
34
Madrigal Pharmaceuticals
MDGL
$11.8B
$343K 0.24%
+1,182
New +$116K
GTLB icon
35
GitLab
GTLB
$6.58B
$314K 0.22%
+6,910
New +$312K
STSA
36
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$160K 0.11%
177,900
– –
KOD icon
37
Kodiak Sciences
KOD
$2.84B
$140K 0.1%
19,622
– –
ABCL icon
38
AbCellera Biologics
ABCL
$2.12B
$127K 0.09%
12,521
– –
NRIX icon
39
Nurix Therapeutics
NRIX
$2.65B
$126K 0.09%
+11,500
New +$139K
SYBX
40
DELISTED
Synlogic
SYBX
$52.2K 0.04%
4,576
– –
CERS icon
41
Cerus
CERS
$474M
$51.7K 0.04%
14,172
– –
NVTA
42
DELISTED
Invitae Corporation
NVTA
$21.1K 0.01%
11,337
– –
RLMD icon
43
Relmada Therapeutics
RLMD
$527M
– –
-5,642
Closed -$209K
TSVT
44
DELISTED
2seventy bio
TSVT
– –
-40,273
Closed -$586K
RETA
45
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-8,265
Closed -$208K
OTIC
46
DELISTED
Otonomy, Inc.
OTIC
– –
-851,000
Closed -$251K
CCXI
47
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-35,830
Closed -$1.85M
1
2

Similar funds

MAM
Mirabaud Asset Management London, United Kingdom $121M AUM 20.69% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
CCM
Candelo Capital Management New York $121M AUM 113.39% 1-Year Est. Return
CCM
CFO Capital Management Fairfield, Connecticut $121M AUM
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
RIP
Reliant Investment Partners Pinehurst, North Carolina $121M AUM 34.77% 1-Year Est. Return
CF
Conquis Financial Milbrae, California $121M AUM 16.22% 1-Year Est. Return
MW
Merited Wealth North Bay Village, Florida $121M AUM

Nan Fung Group Holdings's Q4 2022 Portfolio in Review

As of Q4 2022, Nan Fung Group Holdings held 47 positions worth $145M, down 7.4% from $157M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Nan Fung Group Holdings withdrew a net $8.89M in Q4 2022, closing 5 positions and reducing 4 holdings. Its most notable exit was ChemoCentryx, Inc., an estimated $1.85M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Technology.

Against the trend, Nan Fung Group Holdings opened a new position in Merus worth $1.45M.

  • Nan Fung Group Holdings's largest Q4 2022 buy was Merus: 93,750 shares worth $1.45M.
  • Nan Fung Group Holdings added most to Replimune Group in Q4 2022, an estimated $709K increase.
  • Nan Fung Group Holdings's biggest Q4 2022 reduction was Harmony Biosciences, cutting an estimated $7.82M.
  • Nan Fung Group Holdings fully exited ChemoCentryx, Inc. in Q4 2022, selling an estimated $1.85M.
  • Nan Fung Group Holdings's ten largest holdings make up 82% of its $145M portfolio in Q4 2022.
  • Nan Fung Group Holdings opened 8 new positions and closed 5 in Q4 2022.
  • Nan Fung Group Holdings's portfolio value fell 7.4% quarter-over-quarter to $145M.

Based on Nan Fung Group Holdings's 13F filing for Q4 2022, filed 13 Feb 2023.